Adherium's receipt of Australian R&D Tax Incentive

Adherium Limited (ASX: $ADR) has received $1,515,000 in cash under the Australian R&D Tax Incentive for the 2023 financial year. The company, a leader in respiratory eHealth, remote monitoring, and data management solutions, is developing its app to include machine learning algorithms to better manage asthma and COPD patients.

Dr. Paul Mastoridis on Adherium's R&D Tax Incentive

R&D is the backbone of Adherium, no one else in the world has our unique digital innovations. We must continue to be the leaders in this space and we want to acknowledge the support of the Australian Government for R&D and its importance in developing our business.

Adherium's Australian R&D Tax Incentive and Future Plans

Adherium Limited (ASX: $ADR) has received $1,515,000 under the Australian R&D Tax Incentive for the 2023 financial year. The company is focused on developing its app to include machine learning algorithms to better manage asthma and COPD patients. Dr. Paul Mastoridis, Chief Executive Officer, emphasized the importance of R&D for the company and acknowledged the support of the Australian Government. Adherium's continued investment in research and development, including the use of machine learning/AI functions for its next-generation Hailie® Smartinhaler® devices, demonstrates its commitment to innovation in respiratory eHealth solutions.